Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 6, 2010, Pages 809-817

  Giaccone, Luisa ^a   Festuccia, Moreno ^a   Marengo, Andrea ^a   Resta, Isabel ^a   Sorasio, Roberto ^a   Pittaluga, Fabrizia ^a   Fiore, Francesca ^a   Boccadoro, Mario ^a   Rizzetto, Mario ^a   Bruno, Benedetto ^a   Marzano, Alfredo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Allogeneic stem cell transplantation; Hepatitis B; Lamivudine; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MELPHALAN; THIOTEPA; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; VIRUS REACTIVATION;

ADULT; AGED; BLOOD DONORS; DNA, VIRAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

EID: 77952581398     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.12.533     Document Type: Article

References (44)

1. Knoll A., Boehm S., Hahn J., et al. Reactivation of resolved hepatitis B virus infection after allogenic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004, 33:925-929.
2. Locasciulli A., Alberti A., Bandini G., et al. Allogeneic bone marrow transplantation from HBsAg+ donors: a multicenter study from the Gruppo Italiano di Midollo Osseo (GITMO). Blood 1995, 86:3236-3240.
3. Xunrong L., Yan A.W., Liang R., et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 2001, 11:287-299.
4. Firpi R.J., Nelson D.R. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program 2006, 375-380.
5. Katz L.H., Fraser A., Gafter-Gvili A., et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepatol 2008, 15:89-102.
6. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
7. Marzano A., Angelucci E., Andreone P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-398.
8. Moses S.E., Lim Z.Y., Sudhanva M., et al. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 2006, 78:1560-1563.
9. Hammond S.P., Borchelt A.M., Ukomadu C., et al. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:1049-1059.
10. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335-352.
11. Carosi G., Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008, 40:603-617.
12. Rossi D., Sala L., Minisini R., et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50:604-611.
13. Raimondo G., Allain J.P., Brunetto M.R., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008, 49:652-657.
14. De Feo T.M., Grossi P., Poli F., et al. Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation 2006, 81:76-80.
15. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with hematological malignancies. Br J Haematol 2007, 136:699-712.
16. Keeffe E.B., Dieterich D.T., Han S.H.B., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
17. Mangia A., Antonucci F., Brunetto M., et al. Italian Association for the Study of the Liver (AISF). The use of molecular assays in the management of viral hepatitis. Dig Liver Dis 2008, 40:395-404.
18. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis. Br J Hepatol 2009, 50:227-242.
19. Przepiorka D., Chan K.W., Champlin R.E., et al. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. Bone Marrow Transplant 1995, 16:737-741.
20. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
21. Yeo W., Chan P.K.S., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62:299-307.
22. Marcucci F., Mele A., Spada E., et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006, 91:554-557.
23. Stroffolini T. The changing pattern of hepatitis B virus infection over the past 3 decades in Italy. Dig Liver Dis 2005, 37:622-627.
24. Targhetta C., Cabras M.G., Mamusa A.M., et al. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008, 93:951-952.
25. Yeo W., Chan T.C., Leung N.W., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
26. Chen M.H., Hsiao L.T., Chiou T.J., et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2008, 87:475-480.
27. Liang R., Lau G.K., Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999, 17:394-398.
28. Uhm J.E., Kim K., Lim T.K., et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:463-468.
29. Hamaguchi M., Yamada H., Gondo H., et al. Retrospective study on the impact of hepatitis B and hepatitis C virus infection on hematopoietic stem cell transplantation in Japan. Int J Hematol 2002, 75:324-331.
30. Raimondo G., Pollicino T., Cacciola I., et al. Occult hepatitis B virus infection. J Hepatol 2007, 46:160-170.
31. Matsue K., Aoki T., Odawara J., et al. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 2009, 83:357-364.
32. Michalak T.I., Mulrooney P.M., Coffin C.S. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol 2004, 78:1730-1738.
33. Knöll A., Pietrzyk M., Loss M., et al. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation 2005, 79:1631-1633.
34. Fytili P., Ciesek S., Manns M.P., et al. Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. Transplantation 2006, 81:808-809.
35. Hui C.K., Lie A., Au W.Y., et al. Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005, 5:1437-1445.
36. Martyak L.A., Taqavi E., Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2007, 28:28-38.
37. Rehermann B., Ferrari C., Pasquinelli C., et al. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic-lymphocyte response. Nat Med 1996, 2:1104-1108.
38. Leung N.W.Y., Tam J.S.L., Lau G.T.C., et al. Hepatitis B virus DNA in peripheral blood leucocytes-a comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994, 73:1143-1148.
39. Seth P., Alrajhi A.A., Kagevi I., et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002, 30:189-194.
40. Dhédin N., Douvin C., Kuentz M., et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998, 66:616-619.
41. Aksoy S., Harputluoglu H., Kilickap S., et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007, 48:1307-1312.
42. Onozawa M., Hashino S., Darmanin S., et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008, 14:1226-1230.
43. Hsiao L.T., Chiou T.J., Liu J.H., et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006, 12:84-94.
44. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis. Br J Hepatol 2009, 50:227-242.